HK1208221A1 - Nampt inhibitors nampt - Google Patents

Nampt inhibitors nampt

Info

Publication number
HK1208221A1
HK1208221A1 HK15108839.1A HK15108839A HK1208221A1 HK 1208221 A1 HK1208221 A1 HK 1208221A1 HK 15108839 A HK15108839 A HK 15108839A HK 1208221 A1 HK1208221 A1 HK 1208221A1
Authority
HK
Hong Kong
Prior art keywords
nampt
inhibitors
nampt inhibitors
inhibitors nampt
Prior art date
Application number
HK15108839.1A
Other languages
English (en)
Chinese (zh)
Inventor
Richard F Clark
Bryan SORENSEN
Augustine T Osuma
Robin Frey
Kenton Longenecker
George Doherty
Michael L Curtin
Michael R Michaelides
Ramzi F Sweis
Marina A Pliushchev
Andy Judd
Todd M Hansen
Howard R Heyman
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of HK1208221A1 publication Critical patent/HK1208221A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Molecular Biology (AREA)
HK15108839.1A 2012-05-11 2015-09-10 Nampt inhibitors nampt HK1208221A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261645679P 2012-05-11 2012-05-11
US201261718998P 2012-10-26 2012-10-26
US201361779626P 2013-03-13 2013-03-13
PCT/US2013/040476 WO2013170112A1 (en) 2012-05-11 2013-05-10 Nampt inhibitors

Publications (1)

Publication Number Publication Date
HK1208221A1 true HK1208221A1 (en) 2016-02-26

Family

ID=48576512

Family Applications (2)

Application Number Title Priority Date Filing Date
HK15108839.1A HK1208221A1 (en) 2012-05-11 2015-09-10 Nampt inhibitors nampt
HK15109035.1A HK1208450A1 (en) 2012-05-11 2015-09-16 Nampt inhibitors nampt

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK15109035.1A HK1208450A1 (en) 2012-05-11 2015-09-16 Nampt inhibitors nampt

Country Status (25)

Country Link
US (4) US9187472B2 (es)
EP (1) EP2847192A1 (es)
JP (1) JP2015516435A (es)
KR (1) KR20150007349A (es)
CN (1) CN104428301A (es)
AR (1) AR091022A1 (es)
AU (1) AU2013259344A1 (es)
BR (1) BR112014028042A2 (es)
CA (1) CA2873060A1 (es)
CL (1) CL2014003026A1 (es)
CO (1) CO7151512A2 (es)
CR (1) CR20140573A (es)
DO (1) DOP2014000253A (es)
EC (1) ECSP14030779A (es)
HK (2) HK1208221A1 (es)
IL (1) IL235354A0 (es)
MX (1) MX2014013734A (es)
PE (1) PE20150224A1 (es)
PH (1) PH12014502513A1 (es)
RU (1) RU2014150049A (es)
SG (1) SG11201407372UA (es)
TW (1) TW201350481A (es)
UA (1) UA114323C2 (es)
WO (1) WO2013170112A1 (es)
ZA (1) ZA201407904B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR091022A1 (es) * 2012-05-11 2014-12-30 Abbvie Inc Inhibidores del nampt
US9266891B2 (en) 2012-11-16 2016-02-23 Boehringer Ingelheim International Gmbh Substituted [1,2,4]triazolo[4,3-A]pyrazines that are BRD4 inhibitors
US10144742B2 (en) 2014-04-18 2018-12-04 Millennium Pharmaceuticals, Inc. Quinoxaline compounds and uses thereof
TW201625641A (zh) * 2014-05-22 2016-07-16 健臻公司 Ｎａｍｐｔ抑制劑及方法
CN106459067B (zh) * 2014-06-25 2019-05-31 豪夫迈·罗氏有限公司 用于治疗脊髓性肌萎缩的咪唑并[1，2-a]吡嗪-1基苯甲酰胺化合物
SG11201700039TA (en) * 2014-07-23 2017-02-27 Aurigene Discovery Tech Ltd 4,5-dihydroisoxazole derivatives as nampt inhibitors
CA2974078A1 (en) 2015-01-20 2016-07-28 Millennium Pharmaceuticals, Inc. Quinazoline and quinoline compounds and uses thereof
CN108290878B (zh) * 2015-10-23 2022-04-26 威佛（国际）股份公司 新的膜铁转运蛋白抑制剂
JPWO2017170826A1 (ja) * 2016-03-30 2019-02-14 味の素株式会社 グルカゴン様ペプチド−１受容体作用増強活性を有する化合物
EP3279192A1 (en) * 2016-08-05 2018-02-07 Centre Hospitalier Universitaire Vaudois (CHUV) Piperidine derivatives for use in the treatment of pancreatic cancer
CN109843334A (zh) 2016-10-18 2019-06-04 西雅图基因公司 烟酰胺腺嘌呤二核苷酸补救途径抑制剂的靶向递送
JOP20180036A1 (ar) 2017-04-18 2019-01-30 Vifor Int Ag أملاح لمثبطات فروبورتين جديدة
TW201904613A (zh) 2017-04-27 2019-02-01 美商西雅圖遺傳學公司 季鹼化菸鹼醯胺腺二核苷酸補救合成抑制劑結合物
GB201908453D0 (en) * 2019-06-12 2019-07-24 Enterprise Therapeutics Ltd Compounds for treating respiratory disease
CN114258392A (zh) * 2019-08-21 2022-03-29 卡尔维斯塔制药有限公司 酶抑制剂
JP2023506917A (ja) 2019-12-20 2023-02-20 バイエル・アクチエンゲゼルシヤフト 置換チオフェンカルボキサミド、チオフェンカルボン酸およびその誘導体

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY115155A (en) 1993-09-09 2003-04-30 Upjohn Co Substituted oxazine and thiazine oxazolidinone antimicrobials.
JPH11512429A (ja) 1995-09-15 1999-10-26 ファルマシア・アンド・アップジョン・カンパニー アミノアリールオキサゾリジノン ｎ−オキシド
DE19624659A1 (de) 1996-06-20 1998-01-08 Klinge Co Chem Pharm Fab Neue Pyridylalken- und Pyridylalkinsäureamide
DE19624668A1 (de) 1996-06-20 1998-02-19 Klinge Co Chem Pharm Fab Verwendung von Pyridylalkan-, Pyridylalken- bzw. Pyridylalkinsäureamiden
US20030220234A1 (en) 1998-11-02 2003-11-27 Selvaraj Naicker Deuterated cyclosporine analogs and their use as immunodulating agents
GB9918037D0 (en) 1999-07-30 1999-09-29 Biochemie Gmbh Organic compounds
EP1348434A1 (en) 2002-03-27 2003-10-01 Fujisawa Deutschland GmbH Use of pyridyl amides as inhibitors of angiogenesis
EP1657242A4 (en) * 2003-08-15 2008-10-29 Banyu Pharma Co Ltd IMIDAZOPYRIDINE DERIVATIVES
WO2005085252A1 (en) 2004-03-04 2005-09-15 Biofocus Discovery Limited Imidazo ‘1,2-a’ pyrazine compounds which interact with protein kinases
DE602004009344T2 (de) 2004-04-19 2008-07-10 Symed Labs Ltd., Hyderabad Neues verfahren zur herstellung von linezolid und verwandten verbindungen
EP1768967B1 (en) 2004-07-20 2009-04-22 Symed Labs Limited Novel intermediates for linezolid and related compounds
KR20070045254A (ko) * 2004-08-02 2007-05-02 슈바르츠 파르마 악티엔게젤샤프트 인돌리진 카르복사미드 및 그 아자 및 디아자유도체
JP2008514702A (ja) 2004-09-29 2008-05-08 エーエムアール テクノロジー インコーポレイテッド 新規シクロスポリン類似体およびそれらの薬学的使用
TW200716636A (en) 2005-05-31 2007-05-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
US7514068B2 (en) 2005-09-14 2009-04-07 Concert Pharmaceuticals Inc. Biphenyl-pyrazolecarboxamide compounds
WO2008026018A1 (en) 2006-09-01 2008-03-06 Topotarget Switzerland Sa New method for the treatment of inflammatory diseases
US8796267B2 (en) 2006-10-23 2014-08-05 Concert Pharmaceuticals, Inc. Oxazolidinone derivatives and methods of use
CA2676944C (en) 2007-02-15 2016-01-19 F. Hoffmann-La Roche Ag 2-aminooxazolines as taar1 ligands
BRPI0810362A2 (pt) 2007-04-19 2014-10-29 Concert Pharmaceuticals Inc Compostos de morfolinila deuterados
US7531685B2 (en) 2007-06-01 2009-05-12 Protia, Llc Deuterium-enriched oxybutynin
US20090131485A1 (en) 2007-09-10 2009-05-21 Concert Pharmaceuticals, Inc. Deuterated pirfenidone
US20090118238A1 (en) 2007-09-17 2009-05-07 Protia, Llc Deuterium-enriched alendronate
US20090088416A1 (en) 2007-09-26 2009-04-02 Protia, Llc Deuterium-enriched lapaquistat
US20090082471A1 (en) 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched fingolimod
EP2209774A1 (en) 2007-10-02 2010-07-28 Concert Pharmaceuticals Inc. Pyrimidinedione derivatives
US20090105338A1 (en) 2007-10-18 2009-04-23 Protia, Llc Deuterium-enriched gabexate mesylate
EP2212298B1 (en) 2007-10-18 2013-03-27 Concert Pharmaceuticals Inc. Deuterated etravirine
CA2703591C (en) 2007-10-26 2013-05-07 Concert Pharmaceuticals, Inc. Deuterated darunavir
NZ587350A (en) * 2008-02-20 2012-07-27 Novartis Ag Thiazole derivatives featuring an imidazolidine or triazole derivative as inhibitors of stearoyl-CoA desaturase
EP2098231A1 (en) 2008-03-05 2009-09-09 Topotarget Switzerland SA Use of NAD formation inhibitors for the treatment of ischemia-reperfusion injury
AU2011295724B2 (en) * 2010-09-03 2016-05-12 Forma Tm, Llc 4- { [ ( pyridin- 3 - yl -methyl) aminocarbonyl] amino} benzene - sulfone derivatives as NAMPT inhibitors for therapy of diseases such as cancer
JP5881704B2 (ja) * 2010-09-03 2016-03-09 フォーマ ティーエム， エルエルシー． Ｎａｍｐｔの阻害のための新規な化合物及び組成物
CA2832291C (en) * 2011-04-05 2015-12-01 Pfizer Limited Pyrrolo[2,3-d)pyrimidine tropomyosin-related kinase inhibitors
AR082889A1 (es) 2011-05-09 2013-01-16 Forma Therapeutics Inc Compuestos y composiciones para la inhibicion de nampt
EP2794569B1 (en) * 2011-12-21 2017-05-10 Biota Europe Ltd Heterocyclic urea compounds
WO2013130935A1 (en) * 2012-03-02 2013-09-06 Genentech, Inc. Amido-benzyl sulfoxide derivatives
WO2013127267A1 (en) * 2012-03-02 2013-09-06 Genentech, Inc. Pyridinyl and pyrimidinyl sulfoxide and sulfone derivatives
US10696692B2 (en) * 2012-03-02 2020-06-30 Forma Tm, Llc Amido-benzyl sulfone and sulfoxide derivates
WO2013130943A1 (en) * 2012-03-02 2013-09-06 Genentech, Inc. Alkyl-and di-substituted amido-benzyl sulfonamide derivatives
WO2013127268A1 (en) * 2012-03-02 2013-09-06 Genentech,Inc. Amido-benzyl sulfone and sulfonamide derivatives
AR091022A1 (es) * 2012-05-11 2014-12-30 Abbvie Inc Inhibidores del nampt
WO2014111871A1 (en) * 2013-01-17 2014-07-24 Aurigene Discovery Technologies Limited 4,5-dihydroisoxazole derivatives as nampt inhibitors

Also Published As

Publication number Publication date
EP2847192A1 (en) 2015-03-18
JP2015516435A (ja) 2015-06-11
CL2014003026A1 (es) 2014-12-26
CO7151512A2 (es) 2014-12-29
SG11201407372UA (en) 2014-12-30
PE20150224A1 (es) 2015-03-08
TW201350481A (zh) 2013-12-16
CA2873060A1 (en) 2013-11-14
BR112014028042A2 (pt) 2017-06-27
US9187472B2 (en) 2015-11-17
US20160184282A1 (en) 2016-06-30
US20130303511A1 (en) 2013-11-14
US20160184281A1 (en) 2016-06-30
ECSP14030779A (es) 2015-09-30
HK1208450A1 (en) 2016-03-04
AR091022A1 (es) 2014-12-30
CR20140573A (es) 2015-02-25
PH12014502513A1 (en) 2014-12-15
RU2014150049A (ru) 2016-07-10
IL235354A0 (en) 2014-12-31
MX2014013734A (es) 2015-06-10
DOP2014000253A (es) 2015-01-15
AU2013259344A1 (en) 2014-11-13
WO2013170112A1 (en) 2013-11-14
US9193723B2 (en) 2015-11-24
KR20150007349A (ko) 2015-01-20
CN104428301A (zh) 2015-03-18
US20170135994A9 (en) 2017-05-18
US20130303508A1 (en) 2013-11-14
ZA201407904B (en) 2017-08-30
UA114323C2 (uk) 2017-05-25

Similar Documents

Publication Publication Date Title
HK1208450A1 (en) Nampt inhibitors nampt
ZA201503041B (en) Gdf-8 inhibitors
HK1212681A1 (zh) 葡糖神經酰胺合酶抑制劑
HK1208442A1 (en) Substituted pyrrolopyrimidinylamino-benzothiazolones as mknk kinase inhibitors mknk
EP2683693A4 (en) ROR-GAMMA-T INHIBITORS
HK1207366A1 (en) Thiadiazolidinediones as gsk-3 inhibitors gsk-3
EP2776393A4 (en) NAMPT INHIBITORS
SG11201500973WA (en) Amino-quinolines as kinase inhibitors
ZA201409497B (en) Tetrahydroquinazolinone derivatives as parp inhibitors
HK1211927A1 (en) Aggrecanase inhibitors
HK1209422A1 (en) Fbxo3 inhibitors fbxo3
EP2888010A4 (en) METHODS OF INHIBITING FASCINE
PL2888228T3 (pl) Inhibitory oddziaływania CD40-TRAF6
EP2847201A4 (en) 6-oxo-purin-phosphoribosyl INHIBITORS
EP2882430A4 (en) ANTIBACTERIAL INHIBITORS
HK1213550A1 (zh) 抑制劑
HK1212895A1 (zh) 用於免疫調節的沙奎那韋-
EP2879681A4 (en) INDOINDUBSTITUTED PYRROLOPYRIMIDINYL HIBITORS OF UBA6
GB201219306D0 (en) Nampt inhibitors
EP2836514A4 (en) TIKI INHIBITORS
GB201120474D0 (en) Inhibitors
GB201213825D0 (en) Damper-device for bouncing-device